Oncotelic closes initial 11 units of up to 500-unit offering with 12% notes and warrants

Oncotelic Therapeutics, Inc.

Initial closing of 11 units at $25,000 each in best-efforts offering of up to 500 units.
Each unit includes a $25,000 note bearing 12% annual interest, due 2 years after final closing.
Notes convertible into OTLC common at $0.10/share or EdgePoint AI common at $1.00/share.
Each unit includes 250,000 warrants to buy OTLC common at $0.12/share or 25,000 EdgePoint warrants at $1.25/share.
Minimum of 10 units required; funds held in escrow until minimum met; offering exempt under Reg D Rule 506.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.